One of the most-loved enemies of medical editors, healthcare policy planners, scholars and scientists in the fields of medicine and public health is the companies that are known as "big pharma. " Indeed, our attitude is correct, because these companies keep on pushing products that lead to addiction to opioids and fentanyl (not unlike the addiction to heroin that is perpetrated by "traditional" drug dealers)
and indulge in disease-mongering such as highlighting testosterone insufficiency in males.
2-3 Two former editors of the New England Journal of Medicine, Marcia Angell and Jerome Kassirer, described in detail how "big pharma" works.
Their reports did not receive any credible rebuttal from the pharmaceutical companies.
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However, over the last two decades, the scientific community has been curbing the bad behavior of "big pharma. " Governments have demanded that medical associations should implement compliance policies regarding publicization and commercialization of pharmaceutical products during congresses and events. For talks and papers, disclosure of conflicts of interest by lecturers and authors has become the reality, and there is no chance of turning the clock back. The most important stance certainly came from the International Committee of Medical Journal Editors, when it determined that all randomized clinical trials should be preregistered on public websites before the beginning of participant enrolment, such that this would be a sine qua non condition for further publication in any journal. While "big pharma" loves to push its products, most of these are, in reality, at breakthrough point, as has been seen in relation to statins. On the other hand, the community of editors, public health planners, scholars and scientists in the fields of medicine and public health has been negligent in relation to the actions of the food industry. The community has acted as well-wishers in relation to "alternative" diets. This attitude is erroneous and constitutes a typical double standard.
There is no reason why a critical attitude should not be adopted in relation to the food industry, alternative diets and published papers addressing diets that apply inadequate tools or meta-analyses. In contrast to current levels of understanding of the workings of big pharma, medical journals are less familiar with descriptions of how "big food" works.
The lay press has sometimes adopted a more critical approach than have scientific journals.
One example can be seen in a book by Michael Moss called "Salt, sugar, fat: how the food giant hooked us, " which forms a summary of a series of articles by this author that were published in the New York Times. 7 Recently, this newspaper published an excellent four-page description of how major companies like Nestlé operate in Brazil, with sales of high-caloric foods to poor people. disease confidently claimed that the accumulated conclusions from decades of knowledge acquired through large observational studies should be dismissed. The authors' conclusion was very pretentious, stating that "global dietary guidelines should be reconsidered in the light of these findings. "
12 Meta-analyses have been useful for assessing issues relating to treatments, but they are not an appropriate tool for observational studies relating to diets used in different times and places. 13 More than eight decades of studies showing that consumption of foods containing animal fat was associated with atherosclerosis and cardiovascular events were "invalidated" through a meta-analysis claiming that "butter is back" (in fairness, the authors did not state this, 14,15 but it was consequently expressed thus on the cover of Time magazine).
16
Barnard et al. 13 concluded: "the food industry is well aware of the power of science-driven headlines and has invested in meta-analyses. In the process, nutritional science may be adversely affected. "
Interestingly, contestation of knowledge is a one-way street.
In contrast to some innovative hypotheses such as NOVA, In conclusion, we need to continue to keep a watchful eye on big pharma, while, at the same time, doing this with the same vigor in relation to the "food giants" and "cleansing the temple" of medicine and epidemiology relating to diet and nutrition.
